Longitudinal Glycemic Outcomes in Patients With Thyroid Eye Disease Treated With Teprotumumab
Teprotumumab may be associated with worsening of glycemic control, with the most pronounced and persistent effects in patients with preexisting glycemic disturbances. The varied timing of peak HbA1c and ongoing need for medical treatment highlight the importance of systematic glycemic risk assessment and routine HbA1c monitoring throughout and after treatment to guide clinical management.
Authors
- Suzanne K. Freitag (ORCID: https://orcid.org/0000-0003-0887-1487)
- Lisa Y. Lin (ORCID: https://orcid.org/0000-0002-1215-4571)
- Sierra K. Ha
- Carolina A. Chiou (ORCID: https://orcid.org/0000-0002-0169-9429)
- Natalie Wolkow (ORCID: https://orcid.org/0000-0003-1524-115X)
- Michael K. Yoon (ORCID: https://orcid.org/0000-0002-8793-7685)
- Grace Lee (ORCID: https://orcid.org/0000-0001-7892-2871)
Institutions
- Massachusetts Eye and Ear Infirmary (US)
- Brown University (US)
Publication Details
- Journal
- Ophthalmic Plastic and Reconstructive Surgery
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1097/iop.0000000000003126
- Citations
- 1
- Primary Topic
- Ophthalmology and Eye Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.47